Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

Completed · Phase 1

Conditions studied: Healthy

In brief

1. To evaluate the pharmacokinetics (PK) and relative bioavailability of TG-2349, given as a new capsule formulation and as the original formulation of oral solution, after a single oral dose of 400 mg under fed condition in healthy volunteers. 2. To evaluate the safety and tolerability of TG-2349 in healthy volunteers. 3. To evaluate the ethnic differences in PK and safety between East Asian and Caucasian volunteers.

Key facts

Study ID

NCT02108418

Run by

TaiGen Biotechnology Co., Ltd.

People needed

24

Starts

2014-04-01

Expected to finish

2014-07-01

Last updated by the study team

2014-12-19

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

Where it is running

• WCCT — Cypress, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.